ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-OR44

Monitoring Serum Potassium Concentration in Patients with Severe Hyperkalemia: The Role of Bloodless Artificial Intelligence (AI)-Assisted Electrocardiography

Session Information

Category: Fluid, Electrolytes, and Acid-Base Disorders

  • 1102 Fluid, Electrolyte, and Acid-Base Disorders: Clinical

Authors

  • Chen, Chien-Chou, Tri-Service General Hospital Department of Internal Medicine, Taipei, Taiwan
  • Sung, Chih-Chien, Tri-Service General Hospital Department of Internal Medicine, Taipei, Taiwan
  • Hsu, Yu-Juei, Tri-Service General Hospital Department of Internal Medicine, Taipei, Taiwan
  • Lin, Shih-Hua P., Tri-Service General Hospital Department of Internal Medicine, Taipei, Taiwan
Background

Severe hyperkalemia is a potentially life-threatening emergency requiring prompt recognition with rapid management and surveillance. Although bloodless artificial intelligence (AI)-enabled electrocardiography (ECG) provides real-time detection of severe hyperkalemia, its application to monitor blood potassium (K+) levels during management has not been evaluated. This study aimed to determine the value of AI-enabled ECG (AI-ECG) for blood K+ monitoring in patients with severe hyperkalemia.

Methods

This retrospective cohort study was performed at an emergency department (ED) of a single academic medical center over 2.5 years. Patients with true severe hyperkalemia defined as Lab-K+ ≥ 6.5 mmol/L with matched AI-ECG K+ ≥ 5.1 mmol/L were included. AI-ECG K+ was quantified by ECG12Net as developed previously. The following ECG K+ and Lab-K+ were measured almost simultaneously during or after K+-lowering therapy at least 2 times. Clinical characteristics, therapeutic intervention, and pertinent laboratory data were analyzed.

Results

Seventy-eight patients fulfilled the enrolled criteria. Most of them had acute on chronic kidney injury, advanced CKD not yet on dialysis, and dialysis-dependent renal failure. Their initial Lab-K+ and AI-ECG K+ were 7.2 ± 0.7 and 6.6 ± 0.5 mmol/L, respectively. During and after K+-lowering therapy, both Lab-K+ and ECG-K+ were significantly declined in parallel in the patients both treated medically (n=37) and with hemodialysis group (n=41). Of note, six patients showing persistent ECG-K+ hyperkalemia despite the normalized Lab-K+ levels.

Conclusion

Point-of-care AI-ECG K+ may provide an effective monitoring of blood K+ changes for severe hyperkalemia and also reveal the pseudo-positive patients with the underlying cardiac structure changes or disorders.

Funding

  • Private Foundation Support